| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/08/2007 | US7214379 Method for the purification of marigold oleoresin |
| 05/08/2007 | US7214371 Tissue engineered biografts for repair of damaged myocardium |
| 05/08/2007 | US7214366 Linking a sulfur compound directly to a terminal carbon of polyethyleneglycol, polyalkylene oxides or a polyvinyl alcohol; converting the sulfur to an active ethyl sulfone group having a reactive site located at the second carbon from the sulfone group; modifying biologically active molecules |
| 05/08/2007 | US7214365 Hydrophilic ingredient such as biotin, carnitine and derivatives thereof, creatine and derivatives thereof, folic acid, pyridoxine, niacinamide, polyphenols, ascorbic acid, Hamamelis, Aloe, or panthenol containing as a photostabilizer a di(C 6-24 branched or unbranched alkyl) 2,6-naphthalenedicarboxylate |
| 05/08/2007 | US7214364 Antibiotic for gramnegative bacteria; atomized dry powder |
| 05/08/2007 | US7214221 Multi-stage fluid delivery device and method |
| 05/08/2007 | US7213593 Two-chamber cartridge for propellant-free metering aerosols |
| 05/08/2007 | CA2427764C Transdermal drug delivery system with improved water absorbability and adhesion properties |
| 05/08/2007 | CA2317954C Device for coating granules to be administered orally |
| 05/08/2007 | CA2306837C Treatment of female sexual dysfunction |
| 05/08/2007 | CA2267498C Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 05/08/2007 | CA2262267C Anti-migraine pharmaceutical compositions and process of using |
| 05/08/2007 | CA2235520C Bioadhesive tablets |
| 05/08/2007 | CA2187085C A device and method for acidic buffering |
| 05/08/2007 | CA2178566C In-situ lyophilization of vaginal suppository in unit dose applications and resultant products |
| 05/03/2007 | WO2007051139A2 Diabetes management systems and methods |
| 05/03/2007 | WO2007050975A2 Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
| 05/03/2007 | WO2007050697A2 Compositions and methods for the administration psychotropic drugs which modulate body weight |
| 05/03/2007 | WO2007050631A2 Dosage form with coated active |
| 05/03/2007 | WO2007050580A2 Transdermal drug delivery system with acrylate or methacrylate functional pressure sensitive adhesive composition |
| 05/03/2007 | WO2007050574A1 Formulation comprising a drug of low water solubility and method of use thereof |
| 05/03/2007 | WO2007050543A2 Topical pharmaceutical foam composition |
| 05/03/2007 | WO2007050387A2 Keratin bioceramic compositions |
| 05/03/2007 | WO2007050377A1 Enhanced efficacy benzisoxazole derivative dosage forms and methods |
| 05/03/2007 | WO2007050294A2 Liquid dosage forms having enteric properties of delayed and then sustained release |
| 05/03/2007 | WO2007050181A2 Metal coordinated compositions |
| 05/03/2007 | WO2007050135A2 Process for treating a biological organism |
| 05/03/2007 | WO2007050130A2 Gold surfaces coated with a thermostable, chemically resistant polypeptide layer and applications thereof |
| 05/03/2007 | WO2007050127A1 Non-irritating formulation and method for the intradermal delivery of substances |
| 05/03/2007 | WO2007050088A2 Vertical tool storage device with a curved handle |
| 05/03/2007 | WO2007049978A1 A delivery system |
| 05/03/2007 | WO2007049916A1 Controlled-release formulation containing tamsulosin hydrochloride |
| 05/03/2007 | WO2007049892A1 Transdermal preparations containing hydrophobic non-steroidal anti-inflammatory drugs |
| 05/03/2007 | WO2007049868A1 Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate |
| 05/03/2007 | WO2007049757A1 Inhibitor of osteoclast formation, composition for oral administration and prophylactic or therapeutic agent for bone disease comprising lactoferrin-containing liposome |
| 05/03/2007 | WO2007049726A1 Biodegradable particle and method for producing the same |
| 05/03/2007 | WO2007049626A1 Oral solid preparation containing cabergoline |
| 05/03/2007 | WO2007049587A1 Enteric-coated preparation |
| 05/03/2007 | WO2007049304A2 Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
| 05/03/2007 | WO2007049292A1 Pharmaceutical formulation of losartan |
| 05/03/2007 | WO2007049291A1 Novel solid dosage forms of valsartan and rochlorothiazide |
| 05/03/2007 | WO2007049102A1 Method of preparing an aqueous pharmaceutical composition comprising hydroxypropyl methylcellulose and pharmaceutical c0mp0siti0ns obtainable |
| 05/03/2007 | WO2007048982A1 Coating agent |
| 05/03/2007 | WO2007048922A1 Method for producing a saccharose composition, resulting product and use thereof |
| 05/03/2007 | WO2007048820A2 Micronised azodicarbonamide, the preparation and use thereof |
| 05/03/2007 | WO2007048811A1 Pharmaceutical compositions comprising tricalcium phosphate and calcium carbonate |
| 05/03/2007 | WO2007048464A1 Encapsulation and controlled release of biologically active ingredients with enzymatically degradable microparticulate hyper-branched polymers |
| 05/03/2007 | WO2007048351A1 The oral agent for improving and protecting the function of joint comprising hyaluronic acid-phospholipid complexes |
| 05/03/2007 | WO2007048332A1 A pharmaceutical composition for treating gout and its preparation and use |
| 05/03/2007 | WO2007048326A1 Nanometer targeted drug for magneto-thermotherapy of malignant tumors |
| 05/03/2007 | WO2007048264A1 Dental implant and production method for said implant |
| 05/03/2007 | WO2007048233A1 Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
| 05/03/2007 | WO2007031621A3 Metronidazole-based dermatological foam and emulsions for the production thereof |
| 05/03/2007 | WO2007031620A3 Metronidazole-based dermatological foam and emulsions for the production thereof |
| 05/03/2007 | WO2007020314A3 Formulation of natural triterpenes obtained from the genus olea in liposomes |
| 05/03/2007 | WO2007011396A3 Particles for treatment of pulmonary infection |
| 05/03/2007 | WO2007010337A8 Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors |
| 05/03/2007 | WO2007007198A3 Retinoid immunomodulating kit and composition and uses thereof |
| 05/03/2007 | WO2007002886A3 Compositions and methods for less immunogenic pr0tein-lip1d complexes |
| 05/03/2007 | WO2007001065A3 Method for the preparation of a wet granulated drug product |
| 05/03/2007 | WO2006137856A3 Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility |
| 05/03/2007 | WO2006127841A3 Multi-reservoir implantable pump with variable flow rate capabilities |
| 05/03/2007 | WO2006124585A3 Multilayer drug system for the delivery of galantamine |
| 05/03/2007 | WO2006119957A3 Method for opening hollow structures made from magnetic nanoparticles |
| 05/03/2007 | WO2006117184A3 Veterinary composition |
| 05/03/2007 | WO2006108556A3 Pharmaceutical aerosol composition |
| 05/03/2007 | WO2006081779A3 A pharmaceutical composition containing olanzapine as the active agent and a process for the preparation thereof |
| 05/03/2007 | WO2006074359A3 Non-irritating compositions containing zinc salts |
| 05/03/2007 | WO2006052503A3 Process for granulating particles |
| 05/03/2007 | WO2005086806A3 An advertisement method |
| 05/03/2007 | WO2005074665A3 Method and apparatus to procure and grow medicinal plants |
| 05/03/2007 | WO2005023331A3 Hydrogel nanocompsites for ophthalmic applications |
| 05/03/2007 | WO2005011602A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 05/03/2007 | US20070101448 Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use |
| 05/03/2007 | US20070100448 Microtubes for therapeutic delivery |
| 05/03/2007 | US20070100398 Neural stimulation system and optical monitoring systems and methods |
| 05/03/2007 | US20070100015 Gels for encapsulation of biological meterials |
| 05/03/2007 | US20070099996 Pharmaceutical compositions of acitretin |
| 05/03/2007 | US20070099906 Combinations for the treatment of noeplastic disorders |
| 05/03/2007 | US20070098938 Container method for product integrity and identification |
| 05/03/2007 | US20070098931 Enrobed core |
| 05/03/2007 | US20070098843 Medicament sustained-release particles and method for preparing the same |
| 05/03/2007 | US20070098807 Matrices for drug delivery and methods for making and using the same |
| 05/03/2007 | US20070098806 Kill anthrax on contact, paper and medical instuments; antimicrobial agents of water soluble polymer, acetic acid, formic acid, citric acid, maleic acid, ascorbic acid, salicyclic; oligodynamic gold, zinc, copper, cerium metal ions which react with counter-ions of the polymer |
| 05/03/2007 | US20070098805 Methods of making and using novel griseofulvin compositions |
| 05/03/2007 | US20070098804 Solid particulate tadalafil having a bimodal particle size distribution |
| 05/03/2007 | US20070098803 Small particle compositions and associated methods |
| 05/03/2007 | US20070098802 Organic nanoparticles and associated methods |
| 05/03/2007 | US20070098801 Particles shaped as platelets |
| 05/03/2007 | US20070098800 Therapeutic compositions |
| 05/03/2007 | US20070098799 Mineralized Hydrogels and Methods of Making and Using Hydrogels |
| 05/03/2007 | US20070098798 Method and article to restore function to a flow control location in a patient |
| 05/03/2007 | US20070098797 Modified release composition of at least one form of venlafaxine |
| 05/03/2007 | US20070098796 Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride |
| 05/03/2007 | US20070098795 Pharmaceutical formulation |
| 05/03/2007 | US20070098794 Oxymorphone controlled release formulations |
| 05/03/2007 | US20070098793 Oxymorphone controlled release formulations |
| 05/03/2007 | US20070098792 Oxymorphone controlled release formulations |
| 05/03/2007 | US20070098791 Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride |
| 05/03/2007 | US20070098790 Nutritional supplement for the enhancement of the health of the liver |